This study is for children and young adults up to 19 years old who have recurrent (returned) medulloblastoma, ependymoma, ATRT (atypical teratoid rhabdoid tumor), or other rare brain tumors. Researchers are testing a combination of several drugs: Bevacizumab, Thalidomide, Celecoxib, Fenofibric acid, and Etoposide. These drugs are given to target angiogenesis (the formation of new blood vessels that tumors need to grow) and are delivered at low doses to reduce side effects. The goal is to see how well this treatment works over 8 years. The study is currently unclear on its recruitment status.

Study design

This is an interventional study with a planned enrollment of 232 participants. It is not specified if it is randomized or blinded.

What's involved

Participants will receive Bevacizumab intravenously every two weeks, and Thalidomide, Celecoxib, Fenofibric acid, and Etoposide orally daily or in alternating cycles for one year.

Compensation

Not stated in the trial record.

Follow-up

The study measures efficacy (how well the treatment works) at 8 years, suggesting a long-term follow-up period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.